Momentum Runners

[Canna_Business]

Bitcoin = $1,000 or less in 5 years.

[Canna_Business]

Bitcoin is a scam invented by the Silk Road to buy drugs online... bearish.

[Robertscott]

$EMED During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

[budfoxfun]

$EMED during the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

[budfoxfun]

$EMED Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

[Let's Roll]

$EMED University research centers, doctors, and physicians around the world have overseen treatments using electrotherapy with outstanding results in the reduction of pain for a wide range of acute and chronic conditions. The WellnessPro Plus is an effective complementary treatment modality for pain relief.

[Robertscott]

$EMED With over a million frequencies to choose from, WellnessPro Plus® offers the widest frequency range on the market allowing it to have numerous applications. FDA CLEARED, it features a “future-ready” modular design, making it widely adaptable to new accessories and therapies.

[Let's Roll]

$EMED Electrotherapy can be used to treat a wide range of of acute and chronic pain.
It also supports healing and recovering and can be used for post-surgical discomfort and to boost your body’s natural recovery properties.

[budfoxfun]

$EMED Despite the benefits of a diverse consumer drug market for pain management, the non-medical use of pharmaceutical opioids has triggered new health threats & an escalating drug abuse epidemic.

[budfoxfun]

$EMED University research centers, doctors, and physicians around the world have overseen treatments using electrotherapy with outstanding results in the reduction of pain for a wide range of acute and chronic conditions. The WellnessPro Plus is an effective complementary treatment modality for pain relief.

[budfoxfun]

$EMED Electrotherapy can be used to treat a wide range of of acute and chronic pain.
It also supports healing and recovering and can be used for post-surgical discomfort and to boost your body’s natural recovery properties.

[Robertscott]

$EMED Bio-electrical stimulation is a safe non toxic pain management therapy that activates the body’s innate
ability to heal itself. Therapy provides targeted pain alleviation to specific areas of the body by
modifying its electrical language related to pain, regulating signals and stimulating endogenous opioids
distributed in the nervous systems, particularly in circuits involved in pain modulation, reward,
responses to stress, and autonomic control.

[budfoxfun]

$EMED as the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

[Let's Roll]

$EMED University research centers, doctors, and physicians around the world have overseen treatments using electrotherapy with outstanding results in the reduction of pain for a wide range of acute and chronic conditions. The WellnessPro Plus is an effective complementary treatment modality for pain relief.

[budfoxfun]

$CYCA Cytta Corp Inks Technology Cooperation Agreement with Megh Computing, Inc. https://finance.yahoo.com/news/cytta-corp-inks-technology-cooperation-133000184.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

[Let's Roll]

$EMED Electrotherapy can be used to treat a wide range of of acute and chronic pain.
It also supports healing and recovering and can be used for post-surgical discomfort and to boost your body’s natural recovery properties.

[Robertscott]

$EMED Bio-electrical stimulation is a safe non toxic pain management therapy that activates the body’s innate
ability to heal itself. Therapy provides targeted pain alleviation to specific areas of the body by
modifying its electrical language related to pain, regulating signals and stimulating endogenous opioids
distributed in the nervous systems, particularly in circuits involved in pain modulation, reward,
responses to stress, and autonomic control.

[budfoxfun]

$EMED Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

[budfoxfun]

$PBTS "We're excited to announce that $PBTS is actively in talks with a prestigious education group to expand our offerings! We'll be able to bring more reading materials and kindergartens. Stay tuned for more!"

"We're excited to announce that $PBTS is actively in talks with a prestigious education group to expand our offerings! We'll be able to bring more reading materials and kindergartens. Stay tuned for more! #Education #ArtificialIntelligence #partnership #expansion

— Powerbridge (@PBTS_Tech) April 24, 2023

[Let's Roll]

$EMED University research centers, doctors, and physicians around the world have overseen treatments using electrotherapy with outstanding results in the reduction of pain for a wide range of acute and chronic conditions. The WellnessPro Plus is an effective complementary treatment modality for pain relief.

[Robertscott]

$EMED When it comes to electricity created in the human body, the energy source is chemical and has to do with the composition of the atoms and molecules present. All the elements we take into our bodies, such as oxygen, sodium, potassium, calcium, magnesium etc., have a specific electrical charge. How those molecules are bound together and how they react to other molecules near them is how chemicals create energy. Some of these electrical impulses found naturally in our bodies activate functions needed for healing.

[Let's Roll]

$SGTM Net Revenue for the 2022 fiscal year end was $35,513,231, an increase of 11.24% in Net Revenue from $31,925,731 for the 2021 fiscal year end.

Gross Profit for the 2022 fiscal year end was $8,000,152, an increase of 505.54% in Gross Profit from $1,321,166 for the 2021 fiscal year end.

Net Income from operations for the 2022 fiscal year end was $8,901,214, an increase of 70.28% in Net Income from $5,227,362 for the 2021 fiscal year end.

Assets for the 2022 fiscal year end were $120,365,084, an increase of 80.17% in Assets from $66,805,152 for the 2021 fiscal year end.
Outstanding Shares for the 2022 fiscal year end was 74,631,743, a decrease of 17.5% from the Outstanding Shares of 90,460,425 for the 2021 fiscal year end.

https://seekingalpha.com/pr/19295506-sustainable-green-team-ltd-reports-35_5m-in-revenue-and-120_3m-in-assets-for-fiscal-2022

[budfoxfun]

$EMED ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.

Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED In 2018, 67,367 drug overdose deaths occurred in the United States, 70% of them involved opioids.

https://electromedtech.com/investors-relations/

[budfoxfun]

$EMED University research centers, doctors, and physicians around the world have overseen treatments using electrotherapy with outstanding results in the reduction of pain for a wide range of acute and chronic conditions. The WellnessPro Plus is an effective complementary treatment modality for pain relief.

[Penny_Agent]

Another great CapitalGainsReport article out featuring $EPAZ

CapitalGainsReport: OTC Momentum Watchlist (EPAZ, GTCH, TSOI, SIRC)
The OTC market has always been an attractive destination for investors seeking to capitalize on the potential of small-cap stocks. With many stocks trading below $0.5, the market provides ample opportunities for investors looking for high-risk, high-reward momentum plays. Yesterday, several such stocks witnessed positive gains, and the question now is whether they can sustain that momentum. In this article, we will examine some potential momentum plays on the OTC market and analyze their prospects for the near future.

Epazz Inc. (OTC: EPAZ), a provider of drone technology, blockchain mobile apps, and cloud-based business software solutions, had a successful day on Thursday, finishing up 5.45%. ZenaDrone Inc., an EPAZ spinoff, has been focusing its attention on the development of its flagship drone, the ZenaDrone 1000.

ZenaDrone is positioned as one of the beneficiaries of the overall growth trend in the drone market. The Zenadrone 1000 is equipped with machine learning systems, AI technology, and multispectral sensors, making it suitable for use in various industries such as military, agriculture, and oil and gas. Additionally, the drone's ability to generate 3D interactive environment maps from the data collected by its cameras makes it highly versatile across different sectors.

Most recently, EPAZ announced that ZenaDrone Inc. is expanding its facilities in Dubai, UAE, to increase production of the ZenaDrone 1000. The expansion is needed to meet the requirements of several pilot program agreements that involve the extended use of ZenaDrone 1000 by customers.

Additionally, ZenaDrone has multiple drone demonstrations scheduled, which requires the need for more drones. Last year, ZenaDrone produced 10 ZenaDrone 1000; this year, the goal is to increase production to over 20 drones per month, with the capacity to produce 40 drones in the same facility. This expansion and increased production capacity will allow ZenaDrone to meet its obligations and increase its presence in the drone market.

CEO Shaun Passley, Ph.D., said, "We are encouraged by the level of interest we have received and, based on the pilot program agreements and the number of scheduled demonstrations, it is time to expand to double the size of our production facility."

The U.S. Air Force has expressed interest in using ZenaDrone 1000 for drone cargo delivery, which includes blood transport, and has invited ZenaDrone to conduct tests under battlefield conditions at an overseas base. ZenaDrone is also qualified to submit a Phase II SBIR grant for external funding of its cargo delivery solution, with grants generally up to $1.2 million for a two-year period.

Investors looking for exposure to the promising military drone market could consider Epazz Inc. (OTC: EPAZ) as a potentially attractive penny stock, given the potential for significant revenue growth from its flagship ZenaDrone product and the expanding demand for military drones in the US.

[Let's Roll]

$SGTM 2022 Year In Review Video

[budfoxfun]

$EMED News: Electromedical Technologies Announces Preliminary Unaudited Revenue for Q4 and FY 2022 and update on operations https://finance.yahoo.com/news/electromedical-technologies-announces-preliminary-unaudited-121900011.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

[budfoxfun]

$EMED has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

[Let's Roll]

$EMED Despite the benefits of a diverse consumer drug market for pain managment, the non-medical use of pharmaceutical opioids has triggered new health threats & an escalating drug abuse epidemic.

[Robertscott]

$EMED In 2018, 67,367 drug overdose deaths occurred in the United States, 70% of them involved opioids.

https://electromedtech.com/investors-relations/

[Let's Roll]

$SGTM The Company is a wholesale manufacturer and national supplier of wood-based mulch, soil, including the soil amendment products: HumiSoil® and XLR8® and are lumber products. The Company sells directly to mass merchandisers, home centers, hardware stores, nurseries, garden centers, convenience stores, food stores, and wholesale distributors. The Company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that has been historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation.
To learn more, please visit: https://www.thesustainablegreenteam.com or visit SGTM’s YouTube Channel.

https://www.morningstar.com/news/globe-newswire/8810271/the-sustainable-green-team-ltd-reports-355m-in-revenue-and-1203m-in-assets-for-its-fiscal-2022-audited-ye-and-announces-its-first-annual-shareholder-meeting

[budfoxfun]

$EMED the company's preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED In 2018, 67,367 drug overdose deaths occurred in the United States, 70% of them involved opioids.

https://electromedtech.com/investors-relations/

[budfoxfun]

$EMED Despite the benefits of a diverse consumer drug market for pain managment, the non-medical use of pharmaceutical opioids has triggered new health threats & an escalating drug abuse epidemic.

[Let's Roll]

$EMED University research centers, doctors, and physicians around the world have overseen treatments using electrotherapy with outstanding results in the reduction of pain for a wide range of acute and chronic conditions. The WellnessPro Plus is an effective complementary treatment modality for pain relief.

[Robertscott]

$EMED
The WellnessPro Plus®

triggers our body’s natural processes. Electrical impulses travel from nerves around the injured area to our brain, delivering the unpleasant sensation of pain. WellnessPro Plus® operates by disrupting these pain signals received by our synapses, mimicking our natural electric signals to relieve patients from pain.

Electromedical Technologies brought together some of the leading biomedical researchers from around the world to develop next generation TENS machines. Through product innovation and a forward-thinking approach, we succeeded to develop specific algorithms in electrotherapy that work to alleviate pain.

[Robertscott]

$EMED University research centers, doctors, and physicians around the world have overseen treatments using electrotherapy with outstanding results in the reduction of pain for a wide range of acute and chronic conditions. The WellnessPro Plus is an effective complementary treatment modality for pain relief.

[budfoxfun]

$EMED Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

[budfoxfun]

$EMED Electrotherapy can be used to treat a wide range of of acute and chronic pain.
It also supports healing and recovering and can be used for post-surgical discomfort and to boost your body’s natural recovery properties.

[Let's Roll]

$EMED Electrotherapy can be used to treat a wide range of of acute and chronic pain.
It also supports healing and recovering and can be used for post-surgical discomfort and to boost your body’s natural recovery properties.

[budfoxfun]

$EMED The Company's Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

[budfoxfun]

$EMED Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.

Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[Let's Roll]

$EMED University research centers, doctors, and physicians around the world have overseen treatments using electrotherapy with outstanding results in the reduction of pain for a wide range of acute and chronic conditions. The WellnessPro Plus is an effective complementary treatment modality for pain relief.

[budfoxfun]

$EMED Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

[Robertscott]

$EMED During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

[Robertscott]

$EMED Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.